Bioextrax AbOMXSTO: BIOEX

BIOEX: Sales growth and improved margins signal progress in Bioextrax's commercialization

· Issued by Bioextrax Ab

Net sales increased to 79 tkr in Q1 2025, with operating losses narrowing and key customer projects advancing toward commercialization. Liquidity is secured for the next 12 months following a rights issue.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.